{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:15:39Z","timestamp":1768972539112,"version":"3.49.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81970140 and No.82370161"],"award-info":[{"award-number":["No. 81970140 and No.82370161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>NPM1 mutacute myeloid leukemia (AML) patients have greater heterogeneity. However, data on the comprehensive integration of clinical and genetic data in NPM1mutAML patients are limited, especially in the FLT3 inhibitor era.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from consecutive AML patients with NPM1mut\/FLT3-ITDwt (n\u2009=\u2009203) and NPM1mut\/FLT3-ITDmut (n\u2009=\u2009115) were reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In NPM1mut\/FLT3-ITDwt patients, in multivariate analyses male sex, WBC count \u226519\u2009\u00d7\u2009109\/L, bone marrow blasts \u2265 70%, NPM1 non-A\/B\/D type mutation, TET2 mutation and measurable residual disease (MRD) positivity after the first cycle of consolidation were significantly-associated with poor relapse-free survival (RFS) and survival. Based on the adverse prognostic covariates, patients were classified into low-risk (score 0-2, n\u2009=\u2009113, 64%), intermediate-risk (score 3, n\u2009=\u200943, 25%) and high-risk (score \u22654, n\u2009=\u200920, 11%) subgroups, with significant differences in 3-year probabilities of RFS and survival (all P values &amp;lt; .001). In NPM1mut\/FLT3-ITDmut patients who did not undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR1, single FLT3-ITD mutation, NPM1 non-A\/B\/D type mutation, TET2 mutation and MRD positivity after the first cycle of consolidation, poor RFS; platelet \u226460\u2009\u00d7\u2009109\/L and albumin &amp;lt;40\u2009g\/L, poor survival. Patients were classified into low-risk (score 0-2) allo-HSCT (n\u2009=\u20099, 11%) or non-allo-HSCT (n\u2009=\u200926, 31%), and high-risk (score \u2265 3) allo-HSCT (n\u2009=\u20098, 10%) or non-allo-HSCT (n\u2009=\u200940, 48%). The first 3 subgroups had comparable outcomes, but were significantly superior to the high-risk non-allo-HSCT subgroup (all P values for trend\u2009=\u2009.001-.010)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We identified high-risk AML patients with NPM1mut\/FLT3-ITDwt or NPM1mut\/FLT3-ITDmut who might consider more intensive therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf257","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:12:42Z","timestamp":1755627162000},"source":"Crossref","is-referenced-by-count":2,"title":["Prognostic covariates associated with outcomes in patients with <i>NPM1<\/i>-mutated acute myeloid leukemia"],"prefix":"10.1093","volume":"30","author":[{"given":"Shunjie","family":"Yu","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Yang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Duan","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GuoRui","family":"Ruan","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhen","family":"Qin","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyun","family":"Lai","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Shi","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Tang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Jia","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]},{"name":"Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University , Beijing 100871,","place":["China"]},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, Peking University , Beijing 100191,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044,","place":["China"]},{"name":"Peking University People\u2019s Hospital , Qingdao 266113,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"2025092002374653200_oyaf257-B1","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"key":"2025092002374653200_oyaf257-B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025092002374653200_oyaf257-B5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092002374653200_oyaf257-B6","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025092002374653200_oyaf257-B7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-014-1595-x","article-title":"TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD\u2014mutations","volume":"100","author":"Tian","year":"2014","journal-title":"Int J Hematol"},{"key":"2025092002374653200_oyaf257-B8","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","article-title":"Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv"},{"key":"2025092002374653200_oyaf257-B9","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-Mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025092002374653200_oyaf257-B10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.humpath.2013.03.007","article-title":"CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia","volume":"44","author":"Dang","year":"2013","journal-title":"Hum Pathol"},{"key":"2025092002374653200_oyaf257-B11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.leukres.2013.02.007","article-title":"CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation","volume":"37","author":"Zhu","year":"2013","journal-title":"Leuk Res"},{"key":"2025092002374653200_oyaf257-B12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025092002374653200_oyaf257-B14","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia french association group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025092002374653200_oyaf257-B16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B17","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1182\/bloodadvances.2023009847","article-title":"Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a phase 3b trial","volume":"7","author":"Sierra","year":"2023","journal-title":"Blood Adv"},{"key":"2025092002374653200_oyaf257-B18","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"},{"key":"2025092002374653200_oyaf257-B19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","article-title":"Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-Positive acute myelogenous leukemia","volume":"22","author":"Oran","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025092002374653200_oyaf257-B21","doi-asserted-by":"crossref","first-page":"456.e1","DOI":"10.1016\/j.jtct.2023.03.033","article-title":"FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in acute myeloid leukemia patients with FLT3-ITD after allogeneic hematopoietic stem cell transplantation: a retrospective propensity score-matching study","volume":"29","author":"Zhou","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025092002374653200_oyaf257-B22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis","volume":"10","author":"Chang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025092002374653200_oyaf257-B23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-018-3265-1","article-title":"Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation","volume":"97","author":"Zhao","year":"2018","journal-title":"Ann Hematol"},{"key":"2025092002374653200_oyaf257-B24","volume-title":"ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013)","author":"Shaffer","year":"2013"},{"key":"2025092002374653200_oyaf257-B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-019-03861-1","article-title":"The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia","volume":"99","author":"Gao","year":"2020","journal-title":"Ann Hematol"},{"key":"2025092002374653200_oyaf257-B26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00277-024-06182-0","article-title":"Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia","volume":"104","author":"Yu","year":"2025","journal-title":"Ann Hematol"},{"key":"2025092002374653200_oyaf257-B27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B28","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2025092002374653200_oyaf257-B29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092002374653200_oyaf257-B30","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00277-024-06001-6","article-title":"Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a\u2009&lt;\u20093log reduction of MRD2 predicted poor survival","volume":"103","author":"Duan","year":"2024","journal-title":"Ann Hematol"},{"key":"2025092002374653200_oyaf257-B31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2022-167138","article-title":"Machine learning allows the identification of new co-mutational patterns with prognostic implications in NPM1 mutated AML\u2014results of the European harmony alliance","volume":"140","author":"Hern\u00e1ndez S\u00e1nchez","year":"2022","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B33","first-page":"4527","article-title":"A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2025092002374653200_oyaf257-B34","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"2025092002374653200_oyaf257-B35","doi-asserted-by":"crossref","first-page":"30128","DOI":"10.18632\/oncotarget.25729","article-title":"Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia","volume":"9","author":"Schranz","year":"2018","journal-title":"Oncotarget"},{"key":"2025092002374653200_oyaf257-B36","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"key":"2025092002374653200_oyaf257-B37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","article-title":"Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML","volume":"8","author":"Chan","year":"2024","journal-title":"Blood Adv"},{"key":"2025092002374653200_oyaf257-B38","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia\u2014implications for the European LeukemiaNet risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"key":"2025092002374653200_oyaf257-B39","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1002\/ajh.26730","article-title":"Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1","volume":"97","author":"Wright","year":"2022","journal-title":"Am J Hematol"},{"key":"2025092002374653200_oyaf257-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0350-1","article-title":"Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype","volume":"90","author":"Koh","year":"2009","journal-title":"Int J Hematol"},{"key":"2025092002374653200_oyaf257-B41","doi-asserted-by":"crossref","first-page":"9420","DOI":"10.1002\/cam4.5704","article-title":"Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf257\/64085047\/oyaf257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf257\/64085047\/oyaf257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf257\/64085047\/oyaf257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:37:57Z","timestamp":1758350277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf257\/8238188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf257","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,19]]},"article-number":"oyaf257"}}